Wall Street analysts expect PetIQ Inc (NASDAQ:PETQ) to post earnings of $0.25 per share for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for PetIQ’s earnings, with the highest EPS estimate coming in at $0.28 and the lowest estimate coming in at $0.23. PetIQ reported earnings of $0.29 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 13.8%. The business is expected to issue its next quarterly earnings results after the market closes on Tuesday, November 13th.
On average, analysts expect that PetIQ will report full-year earnings of $0.82 per share for the current year, with EPS estimates ranging from $0.80 to $0.85. For the next fiscal year, analysts anticipate that the business will report earnings of $0.93 per share, with EPS estimates ranging from $0.87 to $1.00. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that that provide coverage for PetIQ.
PetIQ (NASDAQ:PETQ) last posted its earnings results on Tuesday, August 14th. The company reported $0.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.39 by $0.02. PetIQ had a negative net margin of 0.76% and a positive return on equity of 11.40%. The company had revenue of $171.10 million for the quarter, compared to analyst estimates of $148.48 million. The company’s quarterly revenue was up 96.2% compared to the same quarter last year.
In other PetIQ news, major shareholder Ecp Helios Partners Iv, L.P. sold 1,838,836 shares of the stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $37.15, for a total value of $68,312,757.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO John Newland sold 5,500 shares of the stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $26.78, for a total transaction of $147,290.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,064,477 shares of company stock valued at $113,844,980. Company insiders own 45.26% of the company’s stock.
Large investors have recently bought and sold shares of the business. Wasatch Advisors Inc. grew its position in shares of PetIQ by 452.1% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,944,321 shares of the company’s stock valued at $52,224,000 after acquiring an additional 1,592,157 shares during the period. State of New Jersey Common Pension Fund D grew its position in shares of PetIQ by 571.4% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 940,000 shares of the company’s stock valued at $25,248,000 after acquiring an additional 800,000 shares during the period. Pembroke Management LTD bought a new position in shares of PetIQ during the 2nd quarter valued at approximately $18,637,000. Peregrine Capital Management LLC bought a new position in shares of PetIQ during the 3rd quarter valued at approximately $22,254,000. Finally, Massachusetts Financial Services Co. MA grew its position in shares of PetIQ by 89.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 576,968 shares of the company’s stock valued at $15,497,000 after acquiring an additional 272,588 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.
Shares of PETQ traded down $1.02 on Friday, reaching $32.14. The company’s stock had a trading volume of 392,752 shares, compared to its average volume of 466,386. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.00 and a quick ratio of 0.90. PetIQ has a twelve month low of $17.03 and a twelve month high of $43.93. The firm has a market capitalization of $825.68 million, a PE ratio of 82.41, a P/E/G ratio of 1.69 and a beta of 1.58.
PetIQ Company Profile
PetIQ, Inc operates as a pet health and wellness company. It provides veterinarian services and veterinarian-grade pet products, including prescription (Rx) medications, over-the-counter (OTC) flea and tick preventatives, and health and wellness products for dogs and cats. The company offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.
Featured Story: Swap
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.